You are here: Industry Insights > T-ALL

News List

An existing drug opens new possibilities for treating child leukemia firstwordpharma
August 26, 2021
A new study from Linköping University, Sweden, has shown that the tumour-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children.
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL. prnasia
June 21, 2021
Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia.
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL firstwordpharma
June 21, 2021
Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
Using personalized medicine to avoid resistance to leukemia treatment worldpharmanews
May 11, 2021
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting prnasia
April 12, 2021
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, presented updated long-term follow-up data on their TruUCAR-enabled ...